Document is current
Any future updates will be listed below
-
Authors
Loginovic, Pavel https://orcid.org/0000-0002-9701-0234
Wang, Feiyi https://orcid.org/0000-0002-8179-488X
Li, Jiang https://orcid.org/0000-0002-7006-1285
Ferrat, Lauric https://orcid.org/0000-0002-3166-9685
Mirshahi, Uyenlinh L. https://orcid.org/0000-0003-4972-5451
Rao, H. Shanker https://orcid.org/0000-0001-6827-1470
Petzold, Axel https://orcid.org/0000-0002-0344-9749
Tyrrell, Jessica https://orcid.org/0000-0002-9256-6065
Green, Harry D. https://orcid.org/0000-0002-5105-184X
Weedon, Michael N.
Ganna, Andrea
Tuomi, Tiinamaija https://orcid.org/0000-0002-8306-6202
Carey, David J.
,
,
,
Oram, Richard A. https://orcid.org/0000-0003-3581-8980
Braithwaite, Tasanee https://orcid.org/0000-0002-3025-4066
- License Information
-
More Information
Article History
Received: 16 October 2023
Accepted: 9 January 2024
First Online: 28 February 2024
Competing interests
: R.A.O. is a co-investigator on a Randox Laboratories R&D research grant and received translational industry academic funding from Randox Laboratories R&D relating to autoimmune GRS for prediction and classification of disease. There are no established patents, loyalties, or licensing agreements relating to this grant. It is a 3-year grant (February 2022–2025). The approximate value is a £2.2 million program grant on GRS across autoimmune disease. A.P. reports personal fees from Novartis, Heidelberg Engineering, Zeiss, grants from Novartis, outside the submitted work; and is part of the steering committee of the OCTiMS study which is sponsored by Novartis and the Angio-OCT steering committee which is sponsored by Zeiss. He does not receive compensation for these activities. Other authors have no competing interests to declare.
